August 2012
-
A survey sponsored by the University of Michigan’s C. S. Mott Children’s Hospital found support for regulation of e-cigarettes, with 82% of the US adults polled agreeing that the FDA should regulate the products. Approximately… Read more . . .
-
A PD study has shown no statistically significant difference in pulmonary artery pressure effects of Levadex inhaled dihydroergotamine (DHE) compared to placebo, according to MAP Pharmaceutical. The inhaled formulation had a smaller effect on pulmonary… Read more . . .
-
Prosonix has announced the availability of a new co-crystal development and processing service using its ultrasound technology for the manufacture of co-crystal APIs for inhalation products. According to the company, the process creates co-crystals with… Read more . . .
-
According to Archimedes Pharma, the European Commission has granted marketing authorization for the company’s PecFent fentanyl nasal spray for the treatment of breakthrough pain in adult cancer patients. Archimedes submitted an NDA for the product… Read more . . .
-
Quintiles has announced that it will provide commercialization services to Pharmaxis for the launch of Pharmaxis’s Bronchitol mannitol DPI for the treatment of Cystic Fibrosis. Bronchitol has received orphan drug status in both Europe and… Read more . . .
-
Cypress Bioscience of San Diego, California has aquired worldwide licensing rights for Alexza Pharmaceutical’s Staccato Nicotine inhaler for smoking cessation. Alexza will receive $5 million up front, with another $1 million due upon meeting preclinical… Read more . . .
-
Skye Pharma says that it understands why Abbot has decided to return US marketing rights for the Flutiform formoterol fluticasate MDI given the issues raised by the US FDA concerning approval of the drug. According… Read more . . .
-
Archimedes Pharma, which has submitted an NDA for its lead product, PecFent fentanyl nasal spray, announced that it anticipates creating as many as 75 new jobs at its new US headquarters in Bedminster, NJ. The… Read more . . .
-
MannKind Corporation, which is waiting for FDA approval of its Afrezza inhaled insulin, announced that it hopes to raise up to $110 million by lending 9 million shares of its stock to Bank of America.… Read more . . .
-
Cannabis Science and Smokefree Innotec will co-develop pharmaceutical cannabis products for inhalation. Smokefree Innotec, which manufactures electronic cigarettes, will develop the devices, with Cannabis Science developing the formulations. Read the company’s press release Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.